Argenx SE (NASDAQ:ARGX) is one of the 11 Best Stocks to Buy for Investment.
On January 20, TheFly reported that Wells Fargo increased the price target on Argenx SE from $1,264 to $1,317, keeping an Overweight rating on the shares.
Pixabay/Public Domain
Derek Archila from Wells Fargo raised the price target on ARGX following its strong outlook on Argenx’s Vyvgart, according to TheFly. Archila has raised the 2026-2030 Vyvgart outlook by 5-15%. Vyvgart is an antibody used to treat severe autoimmune diseases, such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
The analyst believes Argenx SE’s FY2026 consensus estimate of $5.6 billion is too low given the growth trajectory. Archila expects the company to generate approximately $6.5 billion, considering single-digit quarter-over-quarter growth in Q1 FY2026 and low double-digital quarter-over-quarter growth between Q2 and Q4. Wall Street’s consensus estimate of $1.18 billion for Q1 indicates a growth of almost 65.79% from a year ago.
Over the past six months, Argenx SE’s shares have soared by over 45% as of January 27. Out of 28 analysts covering ARGX, 86% rank the stock as a Buy. ARGX has a median price target of $1,007.86, representing an upside of 16.80%.
Argenx SE is a commercial-stage biopharma company. Argenx is developing therapies to treat autoimmune diseases.
READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.
This article is originally published at Insider Monkey.
